Harvard Bioscience (HBIO) Equity Ratio (2016 - 2025)
Harvard Bioscience (HBIO) has disclosed Equity Ratio for 16 consecutive years, with 0.18 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio fell 63.76% to 0.18 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.18, a 63.76% decrease, with the full-year FY2024 number at 0.5, down 5.98% from a year prior.
- Equity Ratio was 0.18 for Q3 2025 at Harvard Bioscience, down from 0.2 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.53 in Q4 2023 to a low of 0.18 in Q3 2025.
- A 5-year average of 0.46 and a median of 0.5 in 2024 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: grew 8.58% in 2023, then crashed 64.03% in 2025.
- Harvard Bioscience's Equity Ratio stood at 0.51 in 2021, then dropped by 3.29% to 0.5 in 2022, then grew by 7.07% to 0.53 in 2023, then decreased by 5.98% to 0.5 in 2024, then crashed by 63.93% to 0.18 in 2025.
- Per Business Quant, the three most recent readings for HBIO's Equity Ratio are 0.18 (Q3 2025), 0.2 (Q2 2025), and 0.19 (Q1 2025).